Podcast appearances and mentions of allison ostrander

No Agenda Episode 1436 - "Frog of War" "Frog of War Executive Producers: Baronet Sir Data Ops the Wisconsin Millennial Sam Onan James Cherf Madison McClure Sandy McMahon Chap Williams Allison Ostrander Steve Bandstra (Sir BNAdstra) Associate Executive Producers: Michael Gaff Sir Ron Nooren black knight Dame Kenny-Ben Become a member of the 1437 Club, support the show here Boost us with with Podcasting 2.0 Certified apps: Podfriend - Breez - Sphinx - Podstation - Curiocaster - Fountain Title Changes Sir Data Ops the Wisconsin Millennial -> Baronet Knights & Dames Alexander of Middle Cascadia -> Sir Alexander of Middle Cascadia Robert Wicker -> Sir ByHisGrace Mike Salmon -> Sir Ten Lee Stoned Art By: Nick the Rat End of Show Mixes: Amducious - Rolando Gonzalez Engineering, Stream Management & Wizardry Mark van Dijk - Systems Master Ryan Bemrose - Program Director Back Office Aric Mackey Chapters: Dreb Scott Clip Custodian: Neal Jones NEW: and soon on Netflix: Animated No Agenda No Agenda Social Registration Sign Up for the newsletter No Agenda Peerage ShowNotes Archive of links and Assets (clips etc) 1436.noagendanotes.com New: Directory Archive of Shownotes (includes all audio and video assets used) archive.noagendanotes.com RSS Podcast Feed Full Summaries in PDF No Agenda Lite in opus format NoAgendaTorrents.com has an RSS feed or show torrents Last Modified 03/24/2022 15:06:15This page created with the FreedomController Last Modified 03/24/2022 15:06:15 by Freedom Controller  

Show Notes No Agenda Episode 1353 - "Lousy Hummus" "Lousy Hummus" Direct [link] to the mp3 file ShowNotes Archive of links and Assets (clips etc) 1353.noagendanotes.com Sign Up for the newsletter Archive of Shownotes (includes all audio and video assets used) archive.noagendanotes.com The No Agenda News Network- noagendanewsnetwork.com RSS Podcast Feed Experimental IPFS RSS Feed Get the No Agenda News App for your iPhone and iPad Get the NoAgendDroid app for your Android Phone Torrents of each episode via BitLove document.write("Last Modified " + document.lastModified)This page created with the FreedomController Credits "Lousy Hummus" Executive Producers: Mark and Teak Schummer Jamie “Buell” Black Knight Steve of the MF Assemblers Allison Ostrander Associate Executive Producers: Kyle Parker Sir Dave Fugazzotto Duke of The Arabian Peninsula and The American Heartland William Roland Become a member of the 1354 Club, support the show here Boost us with with Podcasting 2.0 Certified apps: Podfriend - Breez - Sphinx - Podstation Art By: TSN End of Show Mixes: Mark and Teak Schummer - Neal Jones The Clip Custodian Engineering, Stream Management & Wizardry Mark van Dijk - Systems Master Ryan Bemrose - Program Director Back Office Aric Mackey Chapters: Dreb Scott Clip Custodian: Neal Jones NEW: and soon on Netflix: Animated No Agenda Sign Up for the newsletter ShowNotes Archive of links and Assets (clips etc) 1353.noagendanotes.com New: Directory Archive of Shownotes (includes all audio and video assets used) archive.noagendanotes.com RSS Podcast Feed No Agenda Lite in opus format NoAgendaTorrents.com has an RSS feed or show torrents document.write("Last Modified " + document.lastModified)This page created with the FreedomController 21119 Keywords

Simple Option Trading Risk Management Strategies How To Trade Stocks & Options Podcast Ep. 357 Learn more at at: https://www.simplertrading.com/recycle/ Today’s podcast covers option trading risk management with Allison Ostrander from Simpler Trading. Option trading risk managment is paramount to trading options successfully. Risk management in option trading cannot be understated as the results can literally wipe out an account. All successful traders have mastered risk management. Successful options traders understand the inherent capital risk management options trading strategies that are needed to keep an account from going to zero with poor risk management trading. It doesn’t matter if you’re looking for risk management forex, or stock trading risk management these trading risk management strategies that we cover in today’s episode will help keep you out of trouble in options trading risk management. Some words are intentionally misspelled for SEO purposes. My Name is Christopher Uhl and I'm an Award Winning Trader, Entrepreneur, Author, Podcaster, Speaker, and Coach that partners with entrepreneurial traders and everyday investors looking to get ahead around the world to help them change their financial futures. Follow these steps to get started on your journey to becoming a 10 Minute Trader too! Step #1: Get the 100% FREE secret weapon that investors all over the world are using to start changing their financial future here: https://www.triplestockprofits.com Step #2: Want to See How We Use Artificial Intelligence To Get Win Rates As High as 90%, Without Wasting Any Time on Useless and Obsolete Technical Analysis... Go Right Now to https://www.tryfinclub.com and see for yourself how they take the guesswork out of trading! Step #3 Do you have the premier options trading broker? If you have any other broker, I want you to stop and go to https://www.trytastyworks.com right now. I have an incredible offer for you, just sign up for a FREE account with Tastyworks using offer code 10MINUTE and I will give you nearly $1,500 in FREE bonuses just for creating a FREE account! It doesn't get any easier than that! Step #4 This Is The BEST Charting Platform I've Ever Used, Get 15% (or more!) Off Your First Year! TRENDSPIDER - The Future of Trading Software https://trendspider.10minutestocktrader.com Step #5 Get A FREE Copy Of The Book I Use As My Business Plan To Grow From Zero to Seven Figures... Expert Secrets - Find Your Message, Build A Tribe, And Change The World... https://expertsecrets.10minutestocktrader.com For more information please visit: https://www.10minutestocktrader.com/legal --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Allison Ostrander and Vitaliy Katsenelson are our guests today. We cover risk and hedging strategies as well as the current market conditions. Options and trading are discussed with Allison, while we take a close look at why Vitaliy sees these as exciting times for value investors. His plan, approach and outlook. Going from bad to […]

Allison Ostrander from Simpler Trading clearly explains what options are all about and how you may benefit from making them part of your investment portfolio.

The FAANG stocks have been leaders of the market over the past 10+ years. Do they still have room to run, or is their time at the top drawing to a close? What tends and data are traders paying attention to with these innovators? Is it time to run, or time to invest? Peter Richon interviews Allison Ostrander on the FAANG stocks and the tech sector.

Cannabis stocks rallied for a second day last Wednesday, buoyed by a historic congressional committee passage of a bill that aims to lift the federal ban on weed, as well as strong gains for Curaleaf after it posted a narrower-than-expected third-quarter loss.  Curaleaf’s U.S.-listed shares CURLF, +15.23% CURA, +15.07% were last up 15%, as investors shrugged off its revenue miss. The Massachusetts-based company posted a loss of $6.8 million, or a penny a share, versus losses of $33.7 million, or 9 cents a share in the year-ago period. Revenue rose to $61.8 million from $21.4 million. Analysts polled by FactSet had expected losses of 2 cents a share on revenue of $63.6 million.  GMP analyst Robert Fagan, who rates the stock a buy, said the numbers were “largely in line with our relatively high expectations.” The revenue number was below his estimate of $67 million.  He highlighted positives, including good cost control, a sequential rise in sales and that vaping fears had only a mue effect on Select’s sales in the quarter. The company acquired the Select brand in May for CS1.27 billion ($954.7 million).  Read now: As pot stocks sink, these two guys just raised $120 million to buy Don’t miss: All the excuses cannabis companies are making for an ugly crop of earnings MKM analyst Bill Kirk raised his fair-value estimate on the stock to C$8 from C$6 but stuck with his neutral rating on the stock.  “Admittedly, after weak earnings reports for most of the sector, it feels nice to use positive numbers when talking about Curaleaf’s profitability,” the analyst wrote in a note. “However, we still can’t quite get there on valuation.” Sentiment on Wednesday was boosted after the House Judiciary Committee voted in favor of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which looks to remove the federal ban on cannabis and expunge past convictions.  Read: Aurora Cannabis stock suffers worst day in more than five years, analyst says ‘it would be fair for investors not to believe them’ The bill, which is being introduced by Committee Chairman Jerrold Nadler, a New York Democrat, passed Wednesday by a 24-10 vote in favor. “The Senate will take its own time, but then the Senate always does,” Nadler said at a press conference on Tuesday to introduce the bill. He also aimed to sound upbeat ahead of Wednesday’s markup session for the bill: “The energy and the political pressure from the various states is growing rapidly. The Senate is subject to that, too. We’ll accomplish this.” Also read: House panel passes bill that aims to legalize marijuana, but top Democrat concedes ‘Senate will take its own time.’ In company news, Harvest Health & Recreation Inc. HRVSF, +8.07% HARV, +6.64% became the latest cannabis company to scale back a previously agreed deal, its plan to buy cannabis licenses in Pennsylvania, Delaware, New Jersey and Maryland from CannaPharmacy Inc. in a deal originally priced at $88 million in cash.  See now: Canada tells cannabis companies to improve disclosures of cross-holdings Instead, the companies have agreed that Harvest Health will acquire Franklin Labs LLC, a unit of CannaPharmacy, for $26 million that will be split between $15 million in cash and an $11 million promissory note. Harvest Chief Executive Jason Vedadi said the new terms will help the company advance its revenue and profitability goals.  Cannabis stocks are still going through a period of retrenchment after a deep slump in stock prices. Many companies are revising deal terms, cutting costs and considering asset sales as the legal market is developing more slowly than expected and companies continue to post losses. Harvest made the announcement as it posted a third-quarter loss of $39.1 million, or 14 cents a share, wider than the $453,000 loss posted in the year-earlier period. The company did not offer a per-share loss number for the year-earlier. Revenue rose to $33.2 million from $11.2 million. There are too few FactSet estimates to offer a reliable consensus. In a similar move, Neptune Wellness Solutions Inc. NEPT, +1.11% NEPT, +3.30%said Wednesday it has reached a mutual agreement with Canopy Growth Corp.CGC, +13.21% WEED, +15.66% to amend and restate their cannabis-processing agreement. The parties have agreed to an amended schedule of processing volumes committed to Neptune by Canopy and to the removal of certain preferential rights granted Canopy related to Neptune’s capacity and pricing.  “Effective June 30, 2020, volume and pricing will be negotiated between the two parties based on market conditions,” Neptune said in a statement. The 3-year term of the deal remains intact. Neptune’s U.S.-listed shares were down 3.7%, while Canopy was up about 12%.

Cannabis stocks rallied for a second day last Wednesday, buoyed by a historic congressional committee passage of a bill that aims to lift the federal ban on weed, as well as strong gains for Curaleaf after it posted a narrower-than-expected third-quarter loss.  Curaleaf’s U.S.-listed shares CURLF, +15.23% CURA, +15.07% were last up 15%, as investors shrugged off its revenue miss. The Massachusetts-based company posted a loss of $6.8 million, or a penny a share, versus losses of $33.7 million, or 9 cents a share in the year-ago period. Revenue rose to $61.8 million from $21.4 million. Analysts polled by FactSet had expected losses of 2 cents a share on revenue of $63.6 million.  GMP analyst Robert Fagan, who rates the stock a buy, said the numbers were “largely in line with our relatively high expectations.” The revenue number was below his estimate of $67 million.  He highlighted positives, including good cost control, a sequential rise in sales and that vaping fears had only a mue effect on Select’s sales in the quarter. The company acquired the Select brand in May for CS1.27 billion ($954.7 million).  Read now: As pot stocks sink, these two guys just raised $120 million to buy Don’t miss: All the excuses cannabis companies are making for an ugly crop of earnings MKM analyst Bill Kirk raised his fair-value estimate on the stock to C$8 from C$6 but stuck with his neutral rating on the stock.  “Admittedly, after weak earnings reports for most of the sector, it feels nice to use positive numbers when talking about Curaleaf’s profitability,” the analyst wrote in a note. “However, we still can’t quite get there on valuation.” Sentiment on Wednesday was boosted after the House Judiciary Committee voted in favor of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, which looks to remove the federal ban on cannabis and expunge past convictions.  Read: Aurora Cannabis stock suffers worst day in more than five years, analyst says ‘it would be fair for investors not to believe them’ The bill, which is being introduced by Committee Chairman Jerrold Nadler, a New York Democrat, passed Wednesday by a 24-10 vote in favor. “The Senate will take its own time, but then the Senate always does,” Nadler said at a press conference on Tuesday to introduce the bill. He also aimed to sound upbeat ahead of Wednesday’s markup session for the bill: “The energy and the political pressure from the various states is growing rapidly. The Senate is subject to that, too. We’ll accomplish this.” Also read: House panel passes bill that aims to legalize marijuana, but top Democrat concedes ‘Senate will take its own time.’ In company news, Harvest Health & Recreation Inc. HRVSF, +8.07% HARV, +6.64% became the latest cannabis company to scale back a previously agreed deal, its plan to buy cannabis licenses in Pennsylvania, Delaware, New Jersey and Maryland from CannaPharmacy Inc. in a deal originally priced at $88 million in cash.  See now: Canada tells cannabis companies to improve disclosures of cross-holdings Instead, the companies have agreed that Harvest Health will acquire Franklin Labs LLC, a unit of CannaPharmacy, for $26 million that will be split between $15 million in cash and an $11 million promissory note. Harvest Chief Executive Jason Vedadi said the new terms will help the company advance its revenue and profitability goals.  Cannabis stocks are still going through a period of retrenchment after a deep slump in stock prices. Many companies are revising deal terms, cutting costs and considering asset sales as the legal market is developing more slowly than expected and companies continue to post losses. Harvest made the announcement as it posted a third-quarter loss of $39.1 million, or 14 cents a share, wider than the $453,000 loss posted in the year-earlier period. The company did not offer a per-share loss number for the year-earlier. Revenue rose to $33.2 million from $11.2 million. There are too few FactSet estimates to offer a reliable consensus. In a similar move, Neptune Wellness Solutions Inc. NEPT, +1.11% NEPT, +3.30%said Wednesday it has reached a mutual agreement with Canopy Growth Corp.CGC, +13.21% WEED, +15.66% to amend and restate their cannabis-processing agreement. The parties have agreed to an amended schedule of processing volumes committed to Neptune by Canopy and to the removal of certain preferential rights granted Canopy related to Neptune’s capacity and pricing.  “Effective June 30, 2020, volume and pricing will be negotiated between the two parties based on market conditions,” Neptune said in a statement. The 3-year term of the deal remains intact. Neptune’s U.S.-listed shares were down 3.7%, while Canopy was up about 12%.

Allison Ostrander is the Director of Risk Tolerance and Options Trader Specialist at "Simpler Trading.” She has a knack for manipulating options to grow small accounts and shares this knowledge with the Simpler Trading Community where she shows folks how to find a Risk Balance to grow their accounts while not over-investing the capital. Allison writes the Simpler Summary for the company's blog, she uses her Theatre degree to help Simpler create teaching materials for their community of traders.

The trade war continues. China and the US are at an impasse. Regardless who's right or wrong, a resolution is elusive. China is making a big bet that President Trump will be defeated. That's what their election analysis team is telling them. If Joe Biden's president they will obviously get a better deal. But this strategy comes with a risk, they may be wrong. And then the stakes will go much higher. Trump will up his demands and China will be left in a real pickle. Maybe the tariffs will go up to 50%. 

The trade war continues. China and the US are at an impasse. Regardless who's right or wrong, a resolution is elusive. China is making a big bet that President Trump will be defeated. That's what their election analysis team is telling them. If Joe Biden's president they will obviously get a better deal. But this strategy comes with a risk, they may be wrong. And then the stakes will go much higher. Trump will up his demands and China will be left in a real pickle. Maybe the tariffs will go up to 50%. 

Colin Cieszynski and Allison Ostrander

Want to know Allison’s take on The Best Way to Trade Any Market? Be sure to tune in today and learn her 25% rule and a low risk high reward strategy to profit using butterflies. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

The past two weeks have seen cannabis stocks take a major hit. But according to Allison Ostrander, it shouldn't be a shock. There's was so much buzz and hype and they moved up so quickly. But she believes it's just a prelude to the next run up in prices. There's too many states and countries getting ready to legalize both medical and recreational cannabis. But you've got to be extremely careful in what stocks you invest in. There's some companies that will come to dominate the industry and others will fade by the wayside. Careful stock picking is essential. 

The past two weeks have seen cannabis stocks take a major hit. But according to Allison Ostrander, it shouldn't be a shock. There's was so much buzz and hype and they moved up so quickly. But she believes it's just a prelude to the next run up in prices. There's too many states and countries getting ready to legalize both medical and recreational cannabis. But you've got to be extremely careful in what stocks you invest in. There's some companies that will come to dominate the industry and others will fade by the wayside. Careful stock picking is essential. 

The past two weeks have seen cannabis stocks take a major hit. But according to Allison Ostrander, it shouldn't be a shock. There's was so much buzz and hype and they moved up so quickly. But she believes it's just a prelude to the next run up in prices. There's too many states and countries getting ready to legalize both medical and recreational cannabis. But you've got to be extremely careful in what stocks you invest in. There's some companies that will come to dominate the industry and others will fade by the wayside. Careful stock picking is essential. 

The past two weeks have seen cannabis stocks take a major hit. But according to Allison Ostrander, it shouldn't be a shock. There's was so much buzz and hype and they moved up so quickly. But she believes it's just a prelude to the next run up in prices. There's too many states and countries getting ready to legalize both medical and recreational cannabis. But you've got to be extremely careful in what stocks you invest in. There's some companies that will come to dominate the industry and others will fade by the wayside. Careful stock picking is essential. 

Making money in the market comes down to buying securities at the right time and selling them after they've gone up and before they've gone down. While this seems self-evident, why is it so hard to do? Well emotions play a large part in it. The consistent winners in this space are those who have a proven strategy and iron-clad discipline. But we're not born knowing how to do it. We've got to learn from somebody and Allison Ostrander has been playing the game for more than 10 years. You can learn her secrets. 

Making money in the market comes down to buying securities at the right time and selling them after they've gone up and before they've gone down. While this seems self-evident, why is it so hard to do? Well emotions play a large part in it. The consistent winners in this space are those who have a proven strategy and iron-clad discipline. But we're not born knowing how to do it. We've got to learn from somebody and Allison Ostrander has been playing the game for more than 10 years. You can learn her secrets. 

Making money in the market comes down to buying securities at the right time and selling them after they've gone up and before they've gone down. While this seems self-evident, why is it so hard to do? Well emotions play a large part in it. The consistent winners in this space are those who have a proven strategy and iron-clad discipline. But we're not born knowing how to do it. We've got to learn from somebody and Allison Ostrander has been playing the game for more than 10 years. You can learn her secrets. 

Making money in the market comes down to buying securities at the right time and selling them after they've gone up and before they've gone down. While this seems self-evident, why is it so hard to do? Well emotions play a large part in it. The consistent winners in this space are those who have a proven strategy and iron-clad discipline. But we're not born knowing how to do it. We've got to learn from somebody and Allison Ostrander has been playing the game for more than 10 years. You can learn her secrets.